Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

NCT05854498 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Liposomal irinotecan
DRUG: TAS102
DRUG: Bevacizumab

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]